![](/img/cover-not-exists.png)
Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer
Kloth, M., Ruesseler, V., Engel, C., Koenig, K., Peifer, M., Mariotti, E., Kuenstlinger, H., Florin, A., Rommerscheidt-Fuss, U., Koitzsch, U., Wodtke, C., Ueckeroth, F., Holzapfel, S., Aretz, S., PropLanguage:
english
Journal:
Gut
DOI:
10.1136/gutjnl-2014-309026
Date:
April, 2015
File:
PDF, 700 KB
english, 2015